Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
22.2M
-
Shares change
-
+745K
-
Total reported value, excl. options
-
$151M
-
Value change
-
+$5.11M
-
Put/Call ratio
-
2.29
-
Number of buys
-
19
-
Number of sells
-
-24
-
Price
-
$6.82
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2018
69 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2018.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.2M shares
of 131M outstanding shares and own 16.95% of the company stock.
Largest 10 shareholders include FMR LLC (5.05M shares), NEA Management Company, LLC (4.81M shares), Polar Capital LLP (3.31M shares), FRANKLIN RESOURCES INC (1.84M shares), GOLDMAN SACHS GROUP INC (1.66M shares), Vivo Capital, LLC (1.21M shares), BlackRock Inc. (961K shares), Abingworth LLP (400K shares), D. E. Shaw & Co., Inc. (389K shares), and AMERIPRISE FINANCIAL INC (367K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.